

Review

## Rheumatoid Arthritis and Vitamin D: A review

Firas Sultan Azzeh.,\* Amany Mokhtar \*\*

(<sup>1</sup>) Department of Clinical Nutrition, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Saudi Arabia\* (<sup>2</sup>) Department Of Community, Environmental, And Occupational Medicine, Faculty Of Medicine Ain Shams University , Cairo , Egypt

**Correspondence:**

**Dr. Firas Sultan Azzeh**

Department of Clinical Nutrition, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Saudi Arabia, P.O. Box: 7067  
Fax: 0096625720000-4238  
E-mail: fsazzeh@uqu.edu.sa

Received: September 30, 2011

Accepted: October 20, 2011

### التهاب المفاصل الروماتيزمي وفيتامين د: مراجعة

د. فراس سلطان العزة<sup>1\*</sup>، د. و أماني مختار<sup>2\*\*</sup>

(<sup>1</sup>) قسم التغذية الإكلينيكية، كلية العلوم الطبية التطبيقية، جامعة أم القرى، مكة المكرمة، المملكة العربية السعودية\*  
(<sup>2</sup>) قسم طب المجتمع و البيئة وطب الصناعات، كلية الطب، جامعة عين شمس، القاهرة، جمهورية مصر العربية

### الملخص العربي

التهاب المفاصل الروماتيزمي هو مرض التهابي مزمن يجعل الغشاء الزليلي في المفاصل ملتهبا، مما يتسبب في انتفاخ المفصل و يجعله صلبا وبه ألم ويحد حركته مما يسيء حركة المفاصل ويتسبب في تشوهه وإعاقة.

يسمى فيتامين د "بفيتامين أشعة الشمس" بحيث يتحول في الجسم إلى هرمون 1،25-ثنائي هيدروكسي فيتامين د3 بفعل التأثير الضوئي للأشعة فوق البنفسجية على الجلد. ويلعب فيتامين د دورا هاما، جنبا إلى جنب مع عنصر الكالسيوم والفسفور، في المحافظة على صحة العظام والأسنان.

وقد وضحت بعض الدراسات المستقبلية انه يوجد علاقة عكسية بين تناول فيتامين د ومرض التهاب المفاصل الروماتيزمي. وعلى الرغم من أن فيتامين د له دور مؤثر في تخفيض حدة أمراض المناعة الذاتية مثل مرض النوع الأول لمرض السكري و مرض تصلب الأنسجة المتعدد، إلا أن دوره في تخفيض حدة التهاب المفاصل الروماتيزمي لا يزال قضية جدل. تم كتابة هذه المراجعة العلمية لتوضيح العلاقات المحتملة بين مرض التهاب المفاصل الروماتيزمي و فيتامين د.

## ABSTRACT

Rheumatoid arthritis is a chronic inflammatory disease in which the synovial membrane of the joint becomes inflamed, resulting in a swelling, stiffness, pain, limited range of motion, joint deformity and disability.

Vitamin D is the "sunshine vitamin" which is converted in the body to a hormone 1, 25-dihydroxyvitamin D<sub>3</sub> by the photolytic action of ultraviolet light on the skin. Vitamin D plays an important role, along with the essential minerals calcium and phosphorus, in the maintenance of healthy bones and teeth.

An inverse association between vitamin D intake and rheumatoid arthritis was found in some prospective studies. Although vitamin D has been implicated in a decreased risk of autoimmune diseases such as type 1 diabetes and multiple sclerosis, its role in decreasing the risk of rheumatoid arthritis remains equivocal. This scientific review is written to illustrate the possible relationships between rheumatoid arthritis and vitamin D.

**Keywords:** Rheumatoid arthritis, Vitamin D, Vitamin D Receptors (VDR)

## INTRODUCTION

Arthritic conditions encompass more than 100 different diseases and conditions affecting the joints, the tissues surrounding the joints and the connective tissue. Arthritic conditions are among the most common diseases in the world and include osteoarthritis, rheumatoid arthritis (RA) and gout.<sup>1</sup> Arthritic conditions affect nearly one in six North Americans and are the leading cause of disability among Americans 18 years of age and older,<sup>2</sup> and about 22% of U.S. adults have arthritis.<sup>3</sup>

Common misconceptions about arthritic conditions are they only affect older persons, that they are an inevitable consequence of aging, they are diagnosed in people of all ages, including children and teens.<sup>4</sup> Juvenile RA affects 70,000 to 100,000 children in US and is one of the most common chronic conditions of childhood.<sup>1</sup> There are several factors known to increase the risk of arthritic conditions, three of which are modifiable: overweight, joint injuries and infections. Non-modifiable risk factors include female sex, age and family history.<sup>1</sup>

RA is an autoimmune disease, in which a person's immune system attacks his or her own healthy tissues.<sup>4</sup> RA is the most common inflammatory arthritis across the world. Although the etiology of RA remains a mystery, a variety of studies suggest that a blend of environmental and genetic factors are responsible, and both affecting the prevalence of autoimmune disease.<sup>5</sup>

Vitamin D is the "sunshine vitamin" which is converted in the body to a hormone 1, 25-dihydroxyvitamin D<sub>3</sub> by the photolytic action of ultraviolet light on the skin. Vitamin D plays an important role, along with the essential minerals calcium and phosphorus, in the maintenance of healthy bones and teeth.<sup>6</sup> Moreover vitamin D sufficiency, especially during the childhood and adolescent years, is critically important not only for bone health, but also for the prevention of many serious chronic diseases, including cancer, cardiovascular heart disease, and autoimmune diseases. It has been suggested that vitamin D deficiency during

infancy and childhood may imprint an increased risk of these chronic diseases for the rest of one's life.<sup>7</sup>

An inverse association between vitamin D intake and RA was found in the prospective cohort study done by the Iowa Women's Health Study.<sup>8</sup> Vitamin D is a hormone essential for bone and mineral homeostasis and is also involved in the regulation of cells in the innate and adaptive immune system through the vitamin D receptor (VDR) as a suppressor of pro-inflammatory responses.<sup>9</sup> Although vitamin D has been implicated in a decreased risk of autoimmune diseases such as type 1 diabetes and multiple sclerosis, its role in decreasing the risk of RA remains equivocal.<sup>10,11</sup> The aim of this review is to summarize the currently available information for the effect of vitamin D on RA disease.

## 2. Rheumatoid Arthritis

### 2.1. Introduction


The name (RA) is based on the term "rheumatic fever", an illness which includes joint pain and is derived from the Greek word *rheumatos* ("flowing"). The suffix *-oid* ("resembling") gives the translation as *joint inflammation that resembles rheumatic fever*. The first recognized description of rheumatoid arthritis was made in 1800 by Dr. Augustin Jacob Landré-Beauvais (1772-1840) of Paris.<sup>12</sup>

Rheumatoid arthritis is a chronic inflammatory disease in which the synovial membrane of the joint becomes inflamed, resulting in a swelling, stiffness, pain, limited range of motion, joint deformity and disability.<sup>13</sup> RA affects approximately 0.8% of the population, is more common in older persons, and affects female three times more often than males.<sup>14</sup>

Although RA primarily affects the joints, it also can affect other tissues, resulting in anorexia, weight loss, fatigue, general itching and stiffness.<sup>4</sup> Extra-articular ("outside the joints") manifestations occur in about 15% of individuals with rheumatoid arthritis. It can be difficult to determine whether disease manifestations are directly caused by the rheumatoid process itself, or from side effects of the medications commonly used to treat it - for example, lung fibrosis from methotrexate, or osteoporosis from corticosteroids.<sup>15</sup>

### 2.2. Pathophysiology

Rheumatoid arthritis is an autoimmune disease, the cause for which is still unknown. It is a systemic (whole body) disorder principally affecting synovial joints. As shown in Figure.1, a normal joint (left) and a joint affected by rheumatoid arthritis (right) are compared. Early changes shown on the left side of the affected joint include inflammation and thickening of the synovial membrane. Late changes shown on the right side of the affected joint include development of pannus, erosion of articular cartilage and bone, and filling of the joint space by pannus.<sup>4</sup>



**Figure 1.** Pathophysiology of RA  
(A normal joint at left and a joint affected by rheumatoid arthritis right)

As with most autoimmune diseases, it is important to distinguish between the causes that trigger the inflammatory process, and those that permit it to persist and progress. Chemical mediators (Cytokines) give rise to inflammation of joint synovium. Constitutional symptoms such as fever, malaise, loss of appetite and weight loss are also due to cytokines released in to the blood stream. Blood vessel inflammation (vasculitis) affecting many other organ systems can give rise to systemic complications.<sup>16</sup>

It has long been suspected that certain infections could be triggers for this disease. The "mistaken identity" theory suggests that an infection triggers an immune response, leaving behind antibodies that should be specific to that organism. The antibodies are not sufficiently specific, though, and set off an immune attack against part of the host. Because the normal host molecule "looks like" a molecule on the offending organism that triggered the initial immune reaction - this phenomenon is called molecular mimicry. Some infectious organisms suspected of triggering rheumatoid arthritis include *Mycoplasma*, *Erysipelothrix*, parvovirus B19 and rubella, but these associations have never been supported in epidemiological studies. Nor has convincing evidence been presented for other types of triggers such as food allergies. There is also no clear evidence that physical and emotional effects, stress and improper diet could be a trigger for the disease. The many negative findings suggest that either the trigger varies, or that it might in fact be a chance event.<sup>17</sup>

Epidemiological studies have confirmed a potential association between RA and two herpesvirus infections: Epstein-Barr virus (EBV) and Human Herpes Virus 6 (HHV-6).<sup>18</sup> Individuals with RA are more likely to exhibit an abnormal immune response to the Epstein-Barr virus.<sup>19,20</sup> The allele HLA-DRB1\*0404 is associated with low frequencies of T cells specific for the EBV glycoprotein 110 and predisposes one to develop RA.<sup>21</sup>

The factors that allow the inflammation, once initiated, to become permanent and chronic, are much more clearly understood. The genetic association with HLA-DR4 is believed to play a major role in this, as well as the newly discovered associations with the gene PTPN22 and with two additional genes.<sup>22</sup> all involved in regulating immune responses. It has also become clear from recent studies that these genetic factors may interact with the most clearly defined environmental risk factor for rheumatoid arthritis, namely cigarette smoking.<sup>23</sup>

### 2.3. Diagnosis

When RA is being clinically suspected, immunological studies are required, such as rheumatoid factor (RF, a specific antibody).<sup>24</sup> A negative RF does not rule out RA; rather, the arthritis is called *seronegative*. During the first year of illness, RF is frequently negative. 80% of individuals eventually convert to seropositive status. RF is also seen in other illnesses, like Sjögren's syndrome, and in approximately 10% of the healthy population, therefore the test is not very specific.<sup>24</sup>

Because of this low specificity, a new serological test has been developed in recent years, which tests for the presence of so called anti-citrullinated protein antibodies (ACPA).<sup>25</sup> Like RF, this test can detect approximately 80% of all RA cases, but is rarely positive if RA is not present, giving it a specificity of around 98%. In addition, ACP antibodies sometimes can be detected in early stages of the disease, or even before onset of clinical disease. Currently, the most common test for ACP antibodies is the anti-CCP (cyclic citrullinated peptide) test.<sup>25</sup> Also, several other blood tests are usually done to discriminate for other causes of arthritis, such as lupus erythematosus. The erythrocyte sedimentation rate (ESR), C-reactive protein,

full blood count, renal function, liver enzymes and other immunological tests (e.g. antinuclear antibody/ANA).<sup>26</sup>

Disease activity can be assessed according to the Disease Activity Score including 28 joint counts (DAS28). Three components of DAS28 test are included: erythrocyte sedimentation rate, patient-assessed global score (0–100), and swollen and tender joint counts (both 0–28). High activity of the disease will be defined as a  $DAS28 > 5.1$ , moderate activity of disease will be defined as a  $3.2 < DAS28 < 5.1$ , and low activity of disease will be defined as a  $DAS28 < 3.2$ .<sup>5</sup>

#### 2.4. Classification criteria

The American College of Rheumatology (ACR) in 1987 (ACR; formerly, the American Rheumatism Association [ARA]) has defined the following criteria for the classification of rheumatoid arthritis:

- Morning stiffness of more than 1 hour most mornings for at least 6 weeks.
- Arthritis and soft-tissue swelling of >3 of 14 joints/joint groups, present for at least 6 weeks
- Arthritis of hand joints, present for at least 6 weeks
- Symmetric arthritis, present for at least 6 weeks
- Subcutaneous nodules in specific places
- Rheumatoid factor at a level above the 95<sup>th</sup> percentile
- Radiological changes suggestive of joint erosion

At least four criteria have to be met for classification as RA.<sup>27</sup>

A joint working group from the ACR and the European League Against Rheumatism (ACR/EULAR) developed a new approach to classifying RA. The work focused on identifying, among patients newly presenting with undifferentiated inflammatory synovitis, factors that best discriminated between those who were and those who were not at high risk for persistent and/or erosive disease. This new classification system redefines the current paradigm of RA by focusing on features at earlier stages of disease that are associated with persistent and/or erosive disease, rather than defining the disease by its late-stage features.<sup>28</sup>

In the new criteria set as shown in Table. 1, classification as “definite RA” is based on the confirmed presence of synovitis in at least 1 joint, absence of an alternative diagnosis that better explains the synovitis, and achievement of a total score of 6 or greater (of a possible 10) from the individual scores in 4 domains: number and site of involved joints (score range 0–5), serologic abnormality (score range 0–3), elevated acute-phase response (score range 0–1), and symptom duration (2 levels; range 0–1).<sup>28</sup>

**Table 1.** The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis.<sup>28</sup>

	<b>Score</b>
Target population (Who should be tested?): Patients who	
1) have at least 1 joint with definite clinical synovitis (swelling)	
2) with the synovitis not better explained by another disease	
Classification criteria for RA (score-base algorithm: add score categories (A-D); a score of $\geq 6/10$ is needed for classification of a patient as having definite RA)	
A. Joint involvement	
1 large joint	0
2-10 large joints	1
1-3 small joints (with or without involvement of large joints)	2
4-10 small joints (with or without involvement of large joints)	3
> 10 joints (at least 1 small joint)	4
B. Serology (at least 1 test result is needed for classification)	5
Negative RF <i>and</i> Negative ACPA	
Low-positive RF <i>or</i> low-positive ACPA	0
High-positive RF <i>or</i> high-positive ACPA	2
C. Acute-phase reactants (at least 1 test result is needed for classification)	3
Normal CRP <i>and</i> normal ESR	
Abnormal CRP <i>or</i> abnormal ESR	0
D. Duration of symptoms	1
< 6 weeks	
$\geq 6$ weeks	0
	1

## 2.5. Treatment

There is no known cure for rheumatoid arthritis. However, many different types of treatment can be used to alleviate symptoms and/or to modify the disease process. The goal of treatment in this chronic disease must be for dual purposes: to alleviate the current symptoms, and to prevent the future destruction of the joints and resulting handicap if the disease is left unchecked. These two goals may not always coincide, while pain relievers may achieve the first goal, they do not have any impact on the long-term consequences. For these reasons, most authorities believe that most RA should be treated by at least one specific anti-rheumatic medication to which other medications and non-medical interventions can be added as needed.<sup>29</sup>

### 2.5.1. Pharmacological treatment

Pharmacological treatment of RA can be divided into disease-modifying antirheumatic drugs (DMARDs), anti-inflammatory agents and analgesics. Anti-inflammatories and analgesics improve pain and stiffness but do not prevent joint damage or slow the disease progression. Anti-inflammatory agents used in RA treatment include glucocorticoids and non-steroidal anti-inflammatory drug (NSAIDs), and analgesics include acetaminophen, opiates, diproqualone and lidocaine topical.<sup>30</sup>

DMARDs have been found to produce durable remissions and delay or halt disease progression. In particular they prevent bone and joint damage from occurring secondary to the uncontrolled inflammation. This is important as such damage is usually irreversible.<sup>29</sup>

There may be other reasons why starting DMARDs early is beneficial as well as prevention of structural joint damage. In the early stage of the disease, the joints are increasingly infiltrated by cells of the immune system that signal to one another and are thought to set up self-perpetuating chronic inflammation. Interrupting this process as early as possible with an effective DMARD (such as methotrexate) appears to improve the outcome of RA for years afterwards. Delaying therapy for as little as few months after the onset of symptoms can result in worse outcomes in the long term. There is therefore considerable interest in establishing the most effective therapy with early arthritis, when they are most responsive to therapy and have the most to gain.<sup>31</sup>

### 2.5.2. Dietary treatment

There is evidence that lower intakes of vegetables, fruits and dietary sources of vitamin C are associated with increased risk of developing RA.<sup>32</sup> However, a research by Canter and his colleague at 2007 which they concluded that there is presently no convincing evidence that selenium, vitamin A, or vitamin C are effective in the treatment of any type of arthritis.<sup>33</sup> Other researchers have been observed that there is a lower risk of developing RA in countries such as Italy and Greece, where oil-rich fish, olive oil, vegetables and fruits are consumed in greater amounts compared to other countries have a higher risk of developing RA.<sup>32</sup>

Omega-3 fatty acids (eicosapentaenoic acid; EPA, and docosahexaenoic acid; DHA) consumption from fish oil and other sources reduce the synthesis of chemicals known to stimulate joints inflammation and cartilage degradation with lesser need to take NSAIDs to relieve pain.<sup>34,35</sup> On the other hand, a diet low in arachidonic acid (omega-6 fatty acids) ameliorates clinical signs of inflammation in patients with RA.<sup>36</sup> Gamma-linolenic acid (GLA) is an omega-6 fatty acid found in oils of some plant seeds and cow milk. There is some preliminary evidence conducted by Little and Parsons in 2000 that GLA may be beneficial for RA. In the body, GLA can be converted into substances that reduce inflammation.<sup>37</sup>

Research on other supplements and herbs for RA symptoms is still in the early stages. Thunder god vine (*Tripterygium wilfordii*) has been used for centuries in traditional Chinese medicine. Extracts are prepared from the skinned root of the herb, as other parts of the plant are highly poisonous.<sup>38</sup> Findings from laboratory and animal studies suggest that thunder god vine may fight inflammation and suppress the immune system. In small clinical trials involving people with RA thunder god vine extracts appeared to provide some relief of symptoms.<sup>39</sup> Thunder god vine can cause severe side effects that can cause diarrhea, stomach upset, hair loss, headache, and skin rash. The herb can also affect the reproductive system, possibly causing menstrual changes in women and infertility in men. Long-term use of thunder god vine may decrease bone mineral density in women, potentially increasing the risk of osteoporosis.<sup>38</sup> In animal studies, extracts of turmeric (*Curcuma longa*) containing the chemical curcumin were found to protect joints from inflammation and damage.<sup>40</sup> Laboratory studies have identified anti-inflammatory compounds in ginger (*Zingiber officinale*) which is gingerol. It has been shown that gingerol is effective against cytokines synthesized and secreted at sites of inflammation.<sup>41</sup>

Citrus fruits, chocolate, alcohol, red meats, flour products, spices and fizzy drinks are often implicated in the aggravation of RA symptoms.<sup>42</sup> Previous investigations have found that a period of fasting followed by a regimented vegetarian diet can decrease RA disease activity. This led to investigations into whether protein and red meat intake play a role in increasing risk of developing RA.<sup>43</sup>

### 3. Vitamin D

Vitamin D deficiency has been a long-standing public health issue. This condition was first described in association with skeletal deformities by Glisson and his group during the mid-17<sup>th</sup> century in London, England. Despite numerous preventive strategies, vitamin D deficiency has remained a global health problem among children.<sup>44</sup>

The National Institution of Health (NIH) reported that serum concentration of 25-Hydroxyvitamin D<sub>3</sub> [25 (OH) D<sub>3</sub>] is the best indicator of the vitamin D status. It reflects vitamin D produced cutaneously and that obtained from food and supplements and has a fairly long circulating half life of 15 days. Different concentrations of serum 25 (OH) D<sub>3</sub> are associated with deficiency, adequacy for bone health, and optimal overall health Table. 2.<sup>45</sup> Several factors potentially affect vitamin D status; these include genetic factors, adiposity and factors affecting the cutaneous synthesis of vitamin D such as skin pigmentation, age, season, latitude, melanin concentration, clothing and use of sunscreens.<sup>46</sup>

**Table 2.** Serum 25-Hydroxyvitamin D [25(OH) D] concentration and health by NIH (2008) \*

ng/ml**	nmol/L**	Health status
<11	<27.5	Associated with vitamin D deficiency and rickets in infant and young children.
<10-15	<25-37.5	Generally considered inadequate for bone and overall health in healthy individuals.
≥30	≥75	Proposed by some as desirable for overall health and disease prevention.
Consistently >200	Consistently >500	Considered potentially toxic, leading to hypercalcemia and hyperphosphatemia.

\*Serum concentration of 25 (OH) D are reported in both nanograms per milliliter (ng/ml) and nanomoles per liter

(nmol/L)\*\*1 ng/ml = 2.5 nmol/L

It is clear that both genetic and environmental factors affect the prevalence of autoimmune diseases. Therefore, the fact that vitamin D has been implicated as a factor in several different



autoimmune diseases suggests that vitamin D might be one of the environmental factors that among others normally participates in the control of self-tolerance.<sup>47</sup> It has been found that polymorphisms in the Vitamin D Receptors (VDR) have been correlated with increased susceptibility of RA.<sup>48,49</sup>

#### 4. Rheumatoid Arthritis and Vitamin D

The discovery of VDR in the cells of the immune system and the fact that activated dendritic cells produce vitamin D hormone suggested that vitamin D could have immunoregulatory properties.<sup>50</sup> VDR, a member of the nuclear hormone receptor super family, was identified in mononuclear cells, dendritic cells, antigen-presenting cells, and activated T-B lymphocytes.<sup>47</sup>

A physiological role for vitamin D in the immune system is supported by the presence of the VDR in primary lymphoid organs. The primary lymphoid organs (bone marrow and thymus) are the centers where the immune system develops and differentiates.<sup>51,52</sup> As a matter of fact, both genetic and environmental factors contribute to the etiology of autoimmune diseases. T cells (lymphocytes that differentiate in the thymus) have been shown to play fundamental roles in autoimmune diseases. Quiescent CD4+ T cells express VDRs at low concentrations, which increases five-fold after their activation.<sup>53</sup> The effects of vitamin D on the acquired, antigen-specific immune response, are characterized by inhibition of T-lymphocyte proliferation,<sup>54</sup> particularly of the Th1 arm (Th 1 is a subset of the T helper cells that secretes cytokines).<sup>55</sup> Treatment of CD4 T cells with vitamin D inhibits Th1 cell proliferation and cytokine production.<sup>56,57</sup>

Addition of vitamin D was shown also to inhibit the expression of the Interleukin-6 (IL-6). IL-6 is an interleukin that acts as both a pro-inflammatory and anti-inflammatory cytokine.<sup>59</sup> Interestingly, in B cells vitamin D has been shown to inhibit antibody secretion and autoantibody production.<sup>60</sup> In vitro, vitamin D inhibits the differentiation of monocytes into dendritic cells and interferes with the stimulatory activity that T cells exert on them.<sup>61</sup> It has been shown that vitamin D is one of the most efficient blockers of dendritic cell differentiation and of interleukin secretion. In vitro vitamin D stimulates phagocytosis and killing of bacteria by macrophages but suppresses the antigen-presenting capacity of these cells and of dendritic cells.<sup>62</sup> Vitamin D has been found to promote the induction of monocytic differentiation to macrophages and modulate macrophage responses, preventing them from releasing inflammatory cytokines and chemokines.<sup>63</sup>

It has been observed that greater intake of vitamin D was associated with a lower risk of RA, as well as lower vitamin D was found associated with higher disease activity.<sup>8</sup> Since lower vitamin D serum levels have been also associated with higher RA disease activity, in a recent study were evaluated serum 25(OH)D3 levels in 64 female RA patients from north Europe (Estonia) and 54 RA patients from south Europe (Italy) during winter and summer and were correlated with the disease activity score (DAS28).<sup>64</sup>

In addition, there may be a higher vitamin D requirement for patients at risk for developing autoimmunity and for those that already have an autoimmune disease such as systemic lupus erythematosus.<sup>65</sup> In fact, the optimal amount of vitamin D to support the immune response may be different from the amount required to prevent vitamin D deficiency or to maintain calcium homeostasis.<sup>66</sup> One review suggest that the optimal plasma 25(OH)D3 concentration lies between 50–80 nmoles/L, other experts suggesting between 75–125 nmol/L.<sup>67</sup>

## CONCLUSIONS

Serum vitamin D levels have been found to correlate inversely with the RA disease activity. Greater intake of vitamin D was associated with a lower risk of RA, as well as a significant clinical improvement was strongly correlated with the immunomodulating potential in vitamin D-treated RA patients.

## REFERENCES

1. Rizzo D. Disorders of skeletal function: rheumatic disorders. In: Porth C, Editor. *Pathophysiology: Concepts of Altered Health Status*, 7<sup>th</sup> edition. PA: Lippincott Williams & Wilkins, 2005. 1417-1440.
2. U.S. Department of Health and Human Services. Prevalence of Disabilities and associated health conditions among adults – United States, 1999. *MMWR Morb Mortal Wkly Report* 2001; 50: 120-125.
3. American College of Rheumatology (ACR), 2010. Retrieved from [http://hosted.ap.org/dynamic/stories/U/US\\_MED\\_ARTHRITIS\\_TOLL?SITE=OHRAV&SECTION=HOME&TEMPLATE=DEFAULT](http://hosted.ap.org/dynamic/stories/U/US_MED_ARTHRITIS_TOLL?SITE=OHRAV&SECTION=HOME&TEMPLATE=DEFAULT).
4. Lee R. Diseases of musculoskeletal system. In: Nelms M, Sucher K, and long S, Editors. *Nutrition Therapy and Pathophysiology*, 1<sup>st</sup> edition. Belmont (USA): Thomson Brooks/Cole, 2007. 843-879.
5. Turhanoglu A, Guler H, Yonden Z, Aslan F, Mansuroglu A, Ozer C. The relationship between vitamin D and disease activity and functional health status in rheumatoid arthritis. *Rhematology International* 2010; 1: 1393-1396.
6. Combs GF. *The Vitamins: Fundamental Aspects in Nutrition and Health*, 2<sup>nd</sup> edition. New York: Academic Press, 1998. 155-182.
7. Holick MF. Vitamin D. In: Shils ME, Editor. *Modern Nutrition in Health and Disease*, 10<sup>th</sup> edition. Philadelphia: Libbincott Williams and Wilkins, 2006. 377-393
8. Merlino LA, Curtis J, Mikuls TR, et al. Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women's Health Study. *Arthritis Rheumatoid* 2004; 50: 72–77.

9. Mathieu C, Van Etten E, Gysemans C, et al. In vitro and in vivo analysis of the immune system of vitamin D receptor knockout mice. *Journal of Bone Mineral Research* 2001; 16: 2057–2065.
10. Hypponen E, Laara E, Reunanen A, et al. Intake of vitamin D and risk of type 1 diabetes: a birth cohort study. *Lancet* 2001; 358: 1500–1503.
11. Holick MF. Vitamin D deficiency. *New England Journal of Medicine* 2007; 357: 266–281.
12. Landré-Beauvais A. The first description of rheumatoid arthritis. Unabridged text of the doctoral dissertation presented in 1800. *Joint Bone Spine* 2001; 68(2): 130–43.
13. Lipsky P. Rheumatoid arthritis. In: Kasper, D; Braunwald, E; Fauci, A; Hausner, S; Longo, D; and Jameson, J, Editors. *Harrison's Principles of Internal Medicine*, 16<sup>th</sup> edition. New York: McGraw-Hill, 2005. 2268-2278.
14. Pattison D, Symmons D, Young A. Does diet have a role in the etiology of rheumatoid arthritis? *Proceedings of the Nutrition Society* 2004, 63: 137-143.
15. Turesson C, O'Fallon W, Crowson C, Gabriel S, Matteson E. "Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years". *Annals of Rheumatic Diseases* 2003; 62(8): 722–727.
16. Choy E, Panayi G. Cytokine pathways and joint inflammation in rheumatoid arthritis. *The New England Journal of Medicine* 2001; 344: 907–916.
17. Edwards J, Cambridge G, Abrahams V. Do self-perpetuating B lymphocytes drive human autoimmune disease? *Immunology* 1999; 97:188-196.
18. Álvarez-Lafuente R, Fernández-Gutiérrez B, de Miguel S, Jover J, Rollin R, Loza E, Clemente D, Lamas J. Potential relationship between herpes viruses and rheumatoid arthritis: analysis with quantitative real time polymerase chain reaction. *Annals of the Rheumatic Diseases* 2005; 64: 1357-1359.
19. Ferrell P, Aitchison C, Pearson G, Tan E. Seroepidemiological study of relationships between Epstein-Barr virus and rheumatoid arthritis. *The Journal of Clinical Investigation* 1981; 67(3): 681–687.
20. Catalano M, Carson D, Slovin S, Richman D, John Vaughan H. Antibodies to Epstein-Barr virus-determined antigens in normal subjects and in patients with seropositive rheumatoid arthritis. *Proceedings of the National Academy of Sciences (USA), Immunology* 1979; 76(11); 5825-5828.

21. Balandraud N, Roudier R. Epstein–Barr virus and rheumatoid arthritis. *Autoimmunity Reviews* 2004; 3(5): 362-367.
22. Plenge RM., Seielstad M, Padyukov L, et al. TRAF1-C5 as a risk locus for rheumatoid arthritis—a genome wide study. *The New England Journal of Medicine* 2007; 357: 1199-209.
23. Padyukov L, Silva C, Stolt P, Alfredsson L, Klareskog L. A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. *Arthritis Rheumatoid* 2004; 50: 3085-3092.
24. American Association for Clinical Chemistry, (September 30, 2006). Lab Tests Online for Rheumatoid Factor (RF). Retrieved from:  
<http://www.labtestsonline.org/understanding/analytes/rheumatoid/test.html>.
25. American Association for Clinical Chemistry, (January 15, 2005). Lab Tests Online for Cyclic Citrullinated Peptide antibody (CCP). Retrieved from:  
<http://www.labtestsonline.org/understanding/analytes/ccp/test.html>
26. American Association for Clinical Chemistry, (December 13, 2004). Lab Tests Online for Antinuclear Antibody (ANA). Retrieved from:  
<http://www.labtestsonline.org/understanding/analytes/ana/test.html>.
27. Arnett F, Edworthy S, Bloch D, McShane D, Fries J, Cooper N, Healey L, Kaplan S, Liang M, Luthra H. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheumatoid* 1988; 31(3): 315-324.
28. Aletaha D, Neogi T, Silman A, et al. 2010 Rheumatoid Arthritis Classification Criteria. An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. *Arthritis & Rheumatism* 2010; 62(9): 2569–2581.
29. O'Dell J. Therapeutic strategies for rheumatoid arthritis. *The New England Journal of Medicine* 2004; 350(25): 2591-602.
30. Hasler P. Biological therapies directed against cells in autoimmune disease. *Springer Seminars in Immunopathology* 2006; 27(4): 443-456.
31. Vital E, Emery P. Advances in the treatment of early rheumatoid arthritis. *American Family Physician* 2005; 72(6): 1002-1004.
32. Rennie K, Hughes J, Jebb, S. Nutritional management of rheumatoid arthritis: a review of the evidence. *Journal of Human Nutrition and Dietitian* 2003; 16: 97-109.

33. Canter P, Wider B, Ernst E. The antioxidant vitamins A, C, E and selenium in the treatment of arthritis: a systematic review of randomized clinical trials. *Rheumatology* 2007; 46:1223–1233.
34. Volker D, Fitzgerald P, Major G, Garg, M. Efficacy of fish oil concentrate in the treatment of rheumatoid arthritis. *Journal of Rheumatology* 2000; 27: 2343-2346.
35. Cleland LG, James MJ, Proudman SM. The role of fish oils in the treatment of rheumatoid arthritis. *Drugs* 2003; 63(9): 845–853.
36. Adam O, Beringer C, Kless T, et al. Anti-inflammatory effects of low arachidonic acid diet and fish oil in patients with rheumatoid arthritis. *Rheumatology International* 2003; 23: 27-36.
37. Little C, Parsons T. Herbal therapy for treating rheumatoid arthritis. *Cochrane Database of Systematic; Reviews* 2000; 4: CD002948.
38. Tao X, Younger J, Fan FZ, et al. Benefit of an extract of *Tripterygium wilfordii* Hook F in patients with rheumatoid arthritis: a double-blind, placebo-controlled study. *Arthritis & Rheumatism* 2002; 46(7): 1735–1743.
39. Canter PH, Lee HS, Ernst EA. Systematic review of randomised clinical trials of *Tripterygium wilfordii* for rheumatoid arthritis. *Phytomedicine* 2006; 13(5): 371–377.
40. Funk JL, Frye JB, Oyarzo JN, et al. Efficacy and mechanism of action of turmeric supplements in the treatment of experimental arthritis. *Arthritis & Rheumatism* 2006; 54(11): 3452–3464.
41. Lantz RC, Chen GJ, Sarihan M, et al. The effect of extracts from ginger rhizome on inflammatory mediator production. *Phytomedicine* 2007; 14(2–3): 123–128.
42. Martin R. The role of nutrition and diet in rheumatoid arthritis. *Proceedings of the Nutrition Society* 1998; 57: 231-234.
43. Liao K, Alfredsson L, Karlson E. Environmental influences on risk for rheumatoid arthritis. *Current Opinion in Rheumatology* 2009; 21(3): 279–283.
44. Leanne MW, Gaboury I, Ladhani M, Zlotkin S. Vitamin D deficiency rickets among children in Canada. *Canadian Medical Association Journal* 2007; 177(2), 161-166.
45. National Institutes of Health (NIH). Dietary Supplement Fact Sheet: Vitamin D. Maryland, USA. 2008.

46. Scientific Advisory Committee on nutrition (SACN). Update on Vitamin D. London. 2007.
47. Arnsen Y, Amital H, Shoenfeld Y. Vitamin D and autoimmunity: new etiological and therapeutical considerations. *Annals of the Rheumatic Diseases* 2007; 66: 1137–1142.
48. Garcia-Lozano JR, Gonzalez-Escribano MF, Valenzuela A, et al. Association of vitamin D receptor genotypes with early onset rheumatoid arthritis. *European Journal of Immunogenetics* 2001; 28: 89–93.
49. Maalej A, Petit-Teixeira E, Michou L, et al. Association study of VDR gene with rheumatoid arthritis in the French population. *Genes and Immunity* 2005; 6:707–711.
50. Fritsche J, Mondal K, Ehrnsperger A, et al. Regulation of 25- hydroxyvitamin D3-1 alpha-hydroxylase and production of 1 alpha 25-dihydroxyvitamin D3 by human dendritic cells. *Blood* 2003; 102:3314–3316.
51. Deluca HF, Cantorna MT. Vitamin D: its role and uses in immunology. *FASEB Journal* 2001; 15: 2579–2585.
52. Langub MC, Reinhardt TA, Horst RL, et al. Characterization of vitamin D receptor immunoreactivity in human bone cells. *Bone* 2000; 27: 383–387.
53. Mahon BD, Wittke A, Weaver V, et al. The targets of vitamin D depend on the differentiation and activation status of CD4 positive T cells. *Journal of Cellular Biochemistry* 2003; 89: 922–932.
54. Lemire JM. Immunomodulatory role of 1,25-dihydroxyvitamin D3. *Journal of Cellular Biochemistry* 1992; 49: 26–31.
55. Mattner F, Smioldo S, Galbiati F, et al. Inhibition of Th1 development and treatment of chronic-relapsing experimental allergic encephalomyelitis by a non-hypercalcemic analogue of 1,25-dihydroxyvitamin D(3). *European Journal of Immunology* 2000; 30: 498–508.
56. Boonstra A, Barrat FJ, Crain C, et al. 1alpha,25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. *Journal of Immunology* 2001; 167: 4974–4980.
57. Van EE. and Mathieu C. Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. *The Journal of Steroid Biochemistry and Molecular Biology* 2005; 97:93–101.
58. Staeva-Vieira TP, Freedman LP. 1,25-dihydroxyvitamin D3 inhibits IFNgamma and IL-4 levels during in vitro polarization of primary murine CD4+ T cells. *Journal of Immunology* 2002; 168: 1181–1189.

59. Stockinger B. Th17 cells: an orphan with influence 4. *Immunology and Cell Biology* 2007; 85: 83–84.
60. Linker-Israeli M, Elstner E, Klinenberg JR, et al. Vitamin D(3) and its synthetic analogs inhibit the spontaneous in vitro immunoglobulin production by SLE-derived PBMC. *Clinical Immunology* 2001; 99: 82–93.
61. Griffin MD, Lutz W, Phan VA, et al. Dendritic cell modulation by 1alpha,25 dihydroxyvitamin D3 and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. *The Proceedings of the National Academy of Sciences Online (US)* 2001; 98: 6800–6805.
62. Griffin MD, Lutz WH, Phan VA, et al. Potent inhibition of dendritic cell differentiation and maturation by vitamin D analogs. *Biochemical and Biophysical Research Communications* 2000; 270: 701–708.
63. Helming L, Bose J, Ehrchen J, et al. 1alpha,25-Dihydroxyvitamin D3 is a potent suppressor of interferon gamma-mediated macrophage activation. *Blood* 2005; 106: 4351–4358.
64. Cutolo M, Otsa K, Laas K, et al. Circannual vitamin d serum levels and disease activity in rheumatoid arthritis: Northern versus Southern Europe. *Clinical and Experimental Rheumatology* 2006; 24: 702–704.
65. Kamen DL, Cooper GS, Bouali H, et al. Vitamin D deficiency in systemic lupus erythematosus. *Autoimmunity Reviews* 2006; 5: 114–117.
66. Rejnmark L, Jorgensen ME, Pedersen MB, et al. Vitamin D insufficiency in Greenlanders on a westernized fare: ethnic differences in calcitropic hormones between Greenlanders and Danes. *Calcified Tissue International* 2004; 74: 255–263.
67. Chatfield SM, Brand C, Ebeling PR, et al. Vitamin D deficiency in general medical in patients in summer and winter. *International Medicine Journal* 2007; 37: 377–382.

Original Article

# Drug-Drug Interactions in Prescribing Practice: The Challenge and Opportunity for Patient Safety

Layla Borham<sup>1</sup>, Mohammed Garout<sup>2</sup>, Alaa Flemban<sup>1</sup>, Safaa Al Sanousy<sup>1</sup>  
Departments of Pharmacology and Toxicology<sup>1</sup> and Community Medicine<sup>2</sup>, Faculty of  
Medicine, Umm Al Qura University, Makkah, Saudi Arabia

**Correspondence:**

Dr. Layla Borham, Pharmacology and Toxicology Department, Faculty of Medicine, Umm Al  
Qura University, Al Abdyah, Makkah, P.O. 6706, Saudi Arabia.  
Tel.: + 966 503 567 843  
Fax: + 96625593498  
E-mail: borhaml@hotmail.com

Received: February 13, 2011

Accepted: April 06.2011

## التفاعلات بين الأدوية في الوصفات الطبية التحدي والفرصة لسلامة المرضى

أ.د. ليلى برهام، د. محمد قاروت\*، د. آلاء فلمبان، د. صفاء السنوسي

قسم علم الأدوية و السموم و قسم صحة المجتمع وطب الحبيج\* بكلية الطب - جامعة أم القرى - مكة المكرمة - المملكة  
العربية السعودية. ص. ب. : 7607

### الملخص العربي

أهداف البحث: يهدف البحث إلى تقييم مدى إنتشار التفاعلات المحتملة بين الأدوية التي تحدث للمرضى في بعض  
المستشفيات السعودية المختارة في مدينة مكة المكرمة بالمملكة العربية السعودية.

وسائل وطرق البحث: تم اختيار ثلاثمائة مريض عشوائياً من إثنين من المستشفيات التعليمية بمدينة مكة المكرمة. تم  
تجميع بيانات المرضى وتضم الجنس، العمر، الجنسية، والأمراض المصاحبة لكل مريض. ولتحديد التفاعلات المحتملة بين  
الأدوية، تم تجميع وتحليل وصفات المرضى والتي تحتوي على دوائين أو أكثر وكذلك سجلاتهم الطبية في خلال فترة أربعة  
أشهر باستخدام برنامجي Micromedex® و فاحص التفاعلات بين الأدوية. تم إدراج الوصفات الطبية بالمرضى في  
أثناء إقامتهم بالمستشفى وكذلك عند خروجهم منها. تم تصنيف التفاعلات بين الأدوية في هذه الدراسة بالكبرى والمعتدلة  
والخفيفة.

النتائج: وُجد في هذه الدراسة أن التفاعلات المحتملة بين الأدوية متكررة في الوصفات الطبية التي تحتوي على أدوية  
متعددة. فالمرضى في هذه الدراسة معرضون لخطر احتمال التفاعلات بين الأدوية خلال الإقامة في المستشفى أو بعد  
الخروج منها بنسبة 75% و 45% على التوالي. وقد كان هناك ارتباط إيجابي بين التفاعلات المحتملة بين الأدوية وبين عدد  
الأدوية الموصوفة، وكانت الوصفات الطبية التي تحتوي على خمسة أدوية أو أقل والتي تحتوي على أكثر من خمسة أدوية  
بها تفاعلات محتملة بين الأدوية بنسبة 26.7% و 49% على التوالي. وقد لوحظ أن التفاعلات المحتملة بين الأدوية تزيد  
مع التقدم في العمر. وكانت التفاعلات المحتملة بين الأدوية معظمها معتدلة (40%) وكبرى (30.3%) بين المرضى  
البالغين، ، في حين أنها كانت معتدلة (50%) بين المرضى كبار السن.

الخلاصة: إن البرامج المبرمجة على إكتشاف التفاعلات المحتملة بين الأدوية جنبا إلى جنب مع المعرفة والخبرة الدوائية،  
ومعرفة عوامل الخطورة الهامة ذات الصلة بالمرضى، بالإضافة إلى التعاون الوثيق بين الأطباء المعالجين والصيادلة  
السريريين، تكون ذات قيمة لخفض عدد التفاعلات الضارة المحتملة ومنع المخاطر المتصلة بالعلاج بالأدوية.